Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 15 of 29 results for hypertrophy

  1. Radiofrequency tissue reduction for turbinate hypertrophy (IPG495)

    Evidence-based recommendations on radiofrequency tissue reduction for turbinate hypertrophy. This involves using radiofrequency energy to close blood vessels that can cause swelling and destroy excess tissue.

  2. Powered microdebrider turbinoplasty for inferior turbinate hypertrophy (IPG498)

    Evidence-based recommendations on powered microdebrider turbinoplasty for inferior turbinate hypertrophy. This involves cutting away some of the swollen membrane covering the turbinates.

  3. Telemetric adjustable pulmonary artery banding for pulmonary hypertension in infants with congenital heart defects (IPG505)

    Evidence-based recommendations on telemetric adjustable pulmonary artery banding for reducing pulmonary hypertension in infants with congenital heart defects. This involves placing a remote-controlled band around the pulmonary artery that can be tightened or loosened to control blood flow.

  4. Otitis media with effusion in under 12s (NG233)

    This guideline covers identifying and managing otitis media with effusion (OME), also known as ‘glue ear’, in children younger than 12 years. It aims to improve hearing and quality of life in children with OME.

  5. Transient loss of consciousness ('blackouts') in over 16s (CG109)

    This guideline covers assessment, diagnosis and referral for people over 16 who have had a transient loss of consciousness (TLoC; also called a blackout). It aims to improve care for people with TLoC by specifying the most effective assessments and recommending when to refer to a specialist.

  6. Balloon valvuloplasty for aortic valve stenosis in adults and children (IPG78)

    Evidence-based recommendations on balloon valvuloplasty for aortic valve stenosis in adults and children. This involves inflating a balloon inserted into the narrow valve to widen it so that blood can flow out more easily.

  7. Percutaneous pulmonary valve implantation for right ventricular outflow tract dysfunction (IPG436)

    Evidence-based recommendations on percutaneous pulmonary valve implantation for right ventricular outflow tract dysfunction. This involves implanting a replacement valve with a wire mesh tube called a stent.

  8. Foker technique for long-gap oesophageal atresia (IPG153)

    Evidence-based recommendations on the Foker technique for long-gap oesophageal atresia. This involves pulling slightly on the broken ends of the oesophagus to encourage them to grow towards each other so they can be stitched together to form a complete oesophagus.

  9. Chronic kidney disease in adults (QS5)

    This quality standard covers the assessment and management of chronic kidney disease in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.

  10. Hypertension: urinary albumin for target organ damage (IND121)

    This indicator covers the percentage of patients with a new diagnosis of hypertension in the preceding 1 April to 31 March who have a record of urinary albumin: creatinine ratio test in the 3 months before or after the date of entry to the hypertension register. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM75

  11. Hypertension: ECG for target organ damage (IND123)

    This indicator covers the percentage of patients with a new diagnosis of hypertension in the preceding 1 April to 31 March who have a record of a 12-lead ECG performed in the 3 months before or after the date of entry to the hypertension register. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM77

  12. Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy (TA913)

    Evidence-based recommendations on mavacamten (Camzyos) for symptomatic obstructive hypertrophic cardiomyopathy.

  13. Multiple frequency bioimpedance devices to guide fluid management in people with chronic kidney disease having dialysis (DG29)

    Evidence-based recommendations on multiple frequency bioimpedance devices to guide fluid management in people with chronic kidney disease having dialysis

  14. Radiofrequency volumetric tissue reduction for turbinate hypertrophy (IPG36)

    This guidance has been updated and replaced by interventional procedures guidance 495.

  15. The Versajet II hydrosurgery system for surgical debridement of acute and chronic wounds and burns (MIB1)

    NICE has developed a Medtech Innovation Briefing (MIB) on the Versajet II hydrosurgery system